Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Express Scripts
Novartis
Cipla
US Department of Justice
McKinsey
Daiichi Sankyo
Teva
AstraZeneca
Moodys

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,874,447

« Back to Dashboard

Summary for Patent: 5,874,447
Title: 4-Phenylpiperidine compounds for treating depression
Abstract:The invention relates to a compound, and pharmaceutically acceptable salts, having the formula I: ##STR1## wherein: R represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by C.sub.1-4 alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl, R.sup.1 represents hydrogen, trifluoro (C.sub.1-4) alkyl, alkyl or alkynyl, X represents hydrogen, alkyl having 1-4 carbon atoms, alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio or aralkoxy, R.sup.2 represents: a C1-C10 alkyl group, a phenyl group optionally substituted by one or more of the following groups: a C1-C10 alkyl group, a halogen group, a nitro group, hydroxy group, and/or an alkoxy group.
Inventor(s): Benneker; Franciscus Bernardus Gemma (Nijmegan, NL), Van Dalen; Frans (Neunen, NL), Lemmens; Jacobus Maria (Mook, NL), Peters; Theodorus Hendricus Antonium (Arnhem, NL), Picha; Frantisek (Brno, CS)
Assignee: Synthon B. V. (Nijmegen, NL)
Application Number:08/872,023
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Dosage form; Use;

Drugs Protected by US Patent 5,874,447

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sebela Ireland Ltd BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-001 Jul 3, 2003 RX Yes No ➤ Subscribe ➤ Subscribe DEPRESSION ➤ Subscribe
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-001 Jul 3, 2003 RX Yes No ➤ Subscribe ➤ Subscribe OBSESSIVE COMPULSIVE DISORDER ➤ Subscribe
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-001 Jul 3, 2003 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF PANIC DISORDER ➤ Subscribe
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 RX Yes No ➤ Subscribe ➤ Subscribe DEPRESSION ➤ Subscribe
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 RX Yes No ➤ Subscribe ➤ Subscribe OBSESSIVE COMPULSIVE DISORDER ➤ Subscribe
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF PANIC DISORDER ➤ Subscribe
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 RX Yes No ➤ Subscribe ➤ Subscribe DEPRESSION ➤ Subscribe
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 RX Yes No ➤ Subscribe ➤ Subscribe OBSESSIVE COMPULSIVE DISORDER ➤ Subscribe
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF PANIC DISORDER ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,874,447

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,900,327 4-phenylpiperidine compounds ➤ Subscribe
7,598,271 Crystalline paroxetine methane sulfonate ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,874,447

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 200781 ➤ Subscribe
Australia 3108097 ➤ Subscribe
Bulgaria 103980 ➤ Subscribe
Bulgaria 64315 ➤ Subscribe
Brazil 9714787 ➤ Subscribe
Canada 2293247 ➤ Subscribe
Czech Republic 295301 ➤ Subscribe
Czech Republic 9904295 ➤ Subscribe
Germany 29724281 ➤ Subscribe
Germany 69704679 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Baxter
Harvard Business School
Queensland Health
Citi
Boehringer Ingelheim
Merck
Chinese Patent Office
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot